3D breast cancer models for drug screening and patient response prediction
ZetaBio Group is a dynamic, research-driven collective focused on the development and evaluation of nanodrug delivery systems for breast cancer therapy, using cutting-edge 3D cellular models. By bridging science and application, we aim to accelerate the discovery of more effective, personalized treatments. Our team fosters open collaborations, rapid knowledge exchange, and high-impact research to push the boundaries of translational oncology.
Our vision
Shaping the Future of 3D-Based Therapeutics against Breast Cancer
ZetaBio envisions a collaborative research ecosystem where scientists connect, co-author impactful publications, and evolve into strategic partners in competitive funding proposals.
By fostering structured subgroups and scaling toward institutional alliances, we aim to bridge ideas and infrastructure—ultimately paving the way for a sustainable, research-driven enterprise with purpose, integrity, and translational impact at its core.
ZetaBio group
Core focus areas
01.
Drug Development & Screening
Design and optimization of advanced drug formulations, delivery systems, and preparation methods.
02.
2D Cell Culture Models
Use of breast cancer cell lines in monolayer cultures for preliminary testing of drug efficacy and cytotoxicity.
03.
3D Cell Culture Systems
Development of 3D breast cancer models that better replicate tumor architecture and microenvironment.
04.
Spheroids & Organoids
Engineering and use of complex multicellular models to study tissue-specific responses to compounds.
05.
Advanced Drug Screening Platforms
Integration of breast cancer-specific cell models with high-content screening tools for evaluating therapeutic efficacy.
06.
Integrated In Vitro Approaches
Combining 2D, 3D, and organoid systems to create robust preclinical models for breast cancer drug development.
Open Collaboration
Ethical Research
Interdisciplinary Thinking
Accessible Science
Covid-19 Contagion
What our group values?
We believe science thrives through open communication, cross-discipline input, and ethical responsibility.
- Eu nunc diam sit sed lectus lectus vehicula ut adipiscing quis hendrerit quis arcu gravida
- Non ut vel ornare sit turpis venenatis vitae in lacus, vel in molestie vestibulum cursus dapibus
Zeta Bio news
Latest news, events & more
Nec habitasse sociis urna urna dignissim et ac parturient sed mi ultricies porttitor ligula eu elementum arcu leo, cum tellus suspendisse dignissim habitant pellentesque.
ZetaBio Attends 2025 BioStart Competition
We’re proud to announce our participation in the BioSTART Competition at the Bio3 Forum in Athens, Greece, September 15-19, 2025.
New Collaboration
As part of its expanding research infrastructure, ZetaBio is now collaborating with certain biotechnology industries around Europe, gaining access to cutting-edge laboratories for 2D and 3D cell culture development.
ZetaBio Welcomes Two New Researchers to the Team
ZetaBio is growing! Two new members have joined our research group, bringing fresh perspectives and expertise.
2025 ERC Advanced Grant call
Open now! The 2025 ERC Advanced Grant call for proposals. Applicants can request up to €2.5 million for a period of up to 5 years. Deadline: 28 August 2025.
Zeta Bio news
Our members affiliations
Nec habitasse sociis urna urna dignissim et ac parturient sed mi ultricies porttitor ligula eu elementum arcu leo, cum tellus suspendisse dignissim habitant pellentesque.
